NEW HAVEN, Conn., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27 at 8:00 a.m. ET in New York City.
A live audio webcast of the presentation will be available at www.arvinas.com on the Events page. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.
Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Arvinas Investor Contact
Randy Teel, VP Corporate Development
Arvinas Media Contact
Cory Tromblee, ScientPR